Tech Snapshot NanoFET 26 25007

Richard P. Feynman Center for Innovation

Technology Snapshot
Technology Licensing Opportunity

NanoFET

Learn more on SAM.gov
Explore additional LANL technologies:
m.lanl.gov/tech-search

NanoFiber Engineering Therapeutics Platform
Value Proposition
NanoFiber Engineered Therapeutics Platform
(NanoFET) offers pharmaceutical and biodefense
organizations a modular, adaptable scaffold for
building next-generation immunotherapies. By
merging self-assembling peptide nanofibers
with interchangeable nanobody and peptide
components, the platform enables rapid
development of targeted treatments that bridge
disease agents directly to the patient’s own
immune cells.

Technology Readiness Level 3

rapid adaptation to new disease targets. A platform
capable of addressing multiple threats through a single reconfigurable architecture would represent a meaningful shift in how therapeutics are developed and deployed.

Technology Description
The NanoFET platform addresses these challenges
through three complementary capabilities. First,
nanobody-nanofiber chimeras (NNMs) can pair a
pathogen-targeting nanobody with an immune-cellengaging nanobody on the same nanofiber scaffold, physically bridging a disease agent to the immune cells best equipped to destroy it. One example is linking a
pan-influenza nanobody to an anti-T-cell nanobody, or an anti-cancer nanobody to a T-cell activator.
Second, a dendritic cell-recruiting peptide conjugated
to the Q11 nanofiber (QDP) activates innate immune
responses in a pathogen-agnostic manner, offering a
broad-spectrum countermeasure that does not require
advance knowledge of the specific threat.

IP Information for S-194657
U.S. Patent pending

Contact Information
[email protected]
Overview
Infectious diseases and chronic conditions such as
cancer continue to impose enormous public health and
economic burdens worldwide. Conventional vaccines and
biologics are typically designed against a single pathogen or target, leaving populations vulnerable when new or
unknown threats emerge. For military personnel and first responders, the absence of broad-spectrum medical
countermeasures means that exposure to an unidentified
pathogen in the field can be met with little more than
supportive care. In cancer immunotherapy, connecting
tumor cells to the patient’s own immune effector cells
remains a formidable engineering challenge; current
bispecific antibody formats are complex to manufacture,